patritumab
daiichi sankyo
['patritumab', 'sclc', 'nsclc']
#asco22 patritumab deruxtecan (her3-dxd) in #egfr wild type nsclc from dr. showed some efficacy - rr 29% and mpfs 10.8m in driver+ nsclc and rr 27% and mpfs 4.2m - looking forward to confirmatory studies. 
Director of Thoracic Oncology & Developmental Therapeutics @LombardiCancer, Associate Professor @Georgetown University #LCSM #HereWeGo #ITYSL He/Him